Generic Name and Formulations:
Moexipril HCl, hydrochlorothiazide; 7.5mg/12.5mg, 15mg/12.5mg, 15mg/25mg; scored tabs.
Various generic manufacturers
Indications for Moexipril/Hydrochlorothiazide:
Hypertension (not for initial therapy).
Take 1 hour before a meal. Switching from monotherapy with either component: 1 tab once daily; adjust at 2–3 week intervals; usual max 30mg/50mg per day. Or, substitute for individually-titrated components.
History of ACEI-associated angioedema. Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment (CrCl ≤40mL/min): not recommended. Discontinue if angioedema, laryngeal edema, jaundice, or marked elevation of hepatic enzymes occurs. Renal or hepatic dysfunction. Salt/volume depletion. CHF. Ischemic heart disease. Aortic or renal artery stenosis. Cerebrovascular disease. Dialysis (esp. high-flux membrane). Surgery. Diabetes. Gout. Asthma. Postsympathectomy. Monitor WBC counts in renal or collagen vascular disease. SLE. Acute myopia and secondary angle-closure glaucoma. Monitor electrolytes and renal function. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
ACE inhibitor + diuretic.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May cause hyperkalemia with K+ sparing diuretics, K+ supplements, or K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH, amphotericin B. May increase lithium, digitalis, diazoxide toxicity. Alcohol, CNS depressants may increase orthostatic hypotension. Adjust antidiabetic, antigout medications. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. May interfere with parathyroid tests. Reduced absorption with cholestyramine and colestipol resins. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Cough, dizziness, fatigue, headache, hyperuricemia, electrolyte disturbances, hyperglycemia, rash, facial flushing, GI upset, angioedema (eg, intestinal), orthostatic hypotension, neutropenia; rare: hepatic failure.
Formerly known under the brand name Uniretic.
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies